For the best experience on the Abcam website please upgrade to a modern browser such as Google Chrome
Every year, dozens of pharmaceutical compounds are withdrawn from the market due to adverse effects not discovered during the preclinical or clinical testing. Many of these adverse effects are subtle and do not lead to visible histopathology, but often lead to mitochondrial dysfunction. Therefore, screening for mitochondrial toxicity in the early development stages of a drug is essential.
Download a copy of our Mitochondrial toxicity Application Guide
Download a copy of our Tools for Detecting Mitochondrial Toxicity